Calliditas Therapeutics AB (publ)

OM:CALTX Stok Raporu

Piyasa değeri: SEK 11.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Renee Aguiar-Lucander

İcra Kurulu Başkanı

SEK 18.4m

Toplam tazminat

CEO maaş yüzdesi36.6%
CEO görev süresi7.4yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi3.6yrs
Yönetim Kurulu ortalama görev süresiless than a year

Son yönetim güncellemeleri

Recent updates

Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Feb 24
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Jan 12
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Dec 22
Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

Sep 22
Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Aug 19
What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

May 26
Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Feb 24
Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Nov 25
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Aug 24
Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

Aug 03
Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

CEO Tazminat Analizi

Renee Aguiar-Lucander'un ücretlendirmesi Calliditas Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-SEK 480m

Mar 31 2024n/an/a

-SEK 525m

Dec 31 2023SEK 18mSEK 7m

-SEK 466m

Sep 30 2023n/an/a

-SEK 451m

Jun 30 2023n/an/a

-SEK 292m

Mar 31 2023n/an/a

-SEK 393m

Dec 31 2022SEK 13mSEK 6m

-SEK 412m

Sep 30 2022n/an/a

-SEK 628m

Jun 30 2022n/an/a

-SEK 608m

Mar 31 2022n/an/a

-SEK 576m

Dec 31 2021SEK 11mSEK 5m

-SEK 500m

Sep 30 2021n/an/a

-SEK 452m

Jun 30 2021n/an/a

-SEK 600m

Mar 31 2021n/an/a

-SEK 501m

Dec 31 2020SEK 7mSEK 3m

-SEK 433m

Sep 30 2020n/an/a

-SEK 286m

Jun 30 2020n/an/a

-SEK 198m

Mar 31 2020n/an/a

-SEK 54m

Dec 31 2019SEK 4mSEK 3m

-SEK 33m

Sep 30 2019n/an/a

-SEK 54m

Jun 30 2019n/an/a

-SEK 35m

Mar 31 2019n/an/a

-SEK 136m

Dec 31 2018SEK 4mSEK 2m

-SEK 132m

Tazminat ve Piyasa: Renee 'nin toplam tazminatı ($USD 1.77M ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 754.57K ).

Tazminat ve Kazançlar: Renee şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Renee Aguiar-Lucander (62 yo)

7.4yrs

Görev süresi

SEK 18,367,000

Tazminat

Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Renee Aguiar-Lucander
Chief Executive Officer7.4yrsSEK 18.37mVeri yok
Fredrik Johansson
Chief Financial Officer7.2yrsVeri yok0%
SEK 0
Lars Stubberud
Vice President of Technical Operations1.8yrsVeri yokVeri yok
Asa Hillsten
Head of IR & Sustainability1.8yrsVeri yokVeri yok
Brian Gorman
Group General Counsel1.8yrsVeri yokVeri yok
Sandra Frithiof
Vice President of Human Resources4.8yrsVeri yokVeri yok
Ann-Kristin Myde
Head of Clinical Development & VP of Project Management7.8yrsVeri yokVeri yok
Richard Philipson
Chief Medical Officer4.3yrsVeri yokVeri yok
Teona Johnson
Head of US Marketing3.6yrsVeri yokVeri yok
David Ferraro
Head of US Sales3.6yrsVeri yokVeri yok
Monika Tornsen
President of North Americaless than a yearVeri yokVeri yok
Christopher Ngai
Vice President of Market Accessno dataVeri yokVeri yok

3.6yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: CALTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Yoshikazu Aoki
Non-Executive Directorless than a yearVeri yokVeri yok
Mark Hensley
Chairmanless than a yearVeri yokVeri yok
Jonathan Barratt
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jürgen Floege
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Richard Lafayette
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Brad Rovin
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Vladimir Tesar
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Hérnan Trimarchi
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Masaya Etoh
Non-Executive Directorless than a yearVeri yokVeri yok
Heather Reich
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Hong Zhang
Member of Scientific Advisory Boardno dataVeri yokVeri yok

0.08yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: CALTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.1 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.